Key facts
- This page summarizes Jake Simson's Form 3 filing for Janux Therapeutics, Inc. (JANX).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 10 Jun 2021, 19:20.
Jake Simson - 10 Jun 2021 Form 3 Insider Report for Janux Therapeutics, Inc. (JANX)
- Reporting relationship
- Director
- Issuer ticker
- JANX
- Reported as of
- 10 Jun 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 10 Jun 2021, 19:20:28 UTC
- Next SEC filing
- 14 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tighe Reardon, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jake Simson filed Form 3 for Janux Therapeutics, Inc. (JANX) on 10 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.
SEC remarks
No securities are beneficially owned.